EXCITATION-CONTRACTION (E-C) coupling in skeletal muscle depends on the activation of dihydropyridine receptors (DHPRs). The skeletal muscle DHPR is composed of the pore-forming, voltage-sensing ␣ 1 1.1-subunit and the auxiliary subunits ␣ 2 /␦ 1 , ␤ 1 , and ␥ 1 (9, 40) . Upon membrane depolarization, DHPRs undergo conformational changes that give rise to three sequential events: charge movement (Q), calcium release, and calcium current (I Ca,L ) (16) . Charge movement is the electrical manifestation of the movement of the voltage sensor in response to changes in membrane potential. Further conformational changes in the ␣ 1 1.1 protein lead to activation of the sarcoplasmic reticulum (SR), calcium release channel, or ryanodine receptor type 1 (RyR1) (16, 36) . The portion of the ␣ 1 1.1 protein involved in controlling calcium release from the SR is the cytoplasmic loop connecting repeats II and III (10, 23, 36) . The last event, I Ca,L , occurs when the ␣ 1 1.1 has suffered additional changes that allow channel opening and calcium influx.
The sequential relationship of the events resulting from DHPR activation would predict that any maneuvers that alter the conformational changes in ␣ 1 1.1 would have a similar effect on Q, calcium release, and I Ca,L . In support of this hypothesis, many experiments have demonstrated that inhibition of the DHPR voltage sensor (e.g., maintained depolarizations, DHPR antagonists, or changes in calcium levels) reduces Q, calcium release, and I Ca,L with a similar time course and magnitude (5, 12, 13, 15, 21, 30) . However, other studies have revealed alternative effects on E-C coupling. For example, the voltage dependence of charge movement and calcium release (or contraction properties) is shifted in the hyperpolarizing direction without changes in the voltage dependence of I Ca,L in the presence of perchlorate (6, 11, 19) or the R615C mutation in the RyR1 (7) . In addition, the DHP nifedipine is also able to induce calcium release (39) and modify contractile activity (22) while blocking I Ca,L . The differential effects of perchlorate and nifedipine on the events generated by DHPRs indicate that E-C coupling can be modulated at different steps, leading to the generation of charge movement, calcium release, and I Ca,L .
We have recently reported that the analgesic and antiepileptic drug gabapentin (GBP) causes a modest reduction of I Ca,L in mouse skeletal myotubes (2) . In the present paper we have extended those studies and examined the effect of GBP on charge movement and calcium release in mouse myotubes. Interestingly, GBP binds to ␣ 2 /␦ 1 -subunits from brain and skeletal muscle with similar kinetics and high affinity (k d ϭ 38 nM in brain and 29 nM in skeletal muscle) (17, 34) . Gee et al. (17) have also shown that, from 14 different tissues examined in the rat, the highest level of GBP-binding sites occurs in skeletal muscle. Therefore, this agent is unique because it binds to a subunit of the DHPR complex other than the ␣ 1 1.1, which is considered to be the voltage sensor. Our present studies demonstrate that GBP increases charge movement and decreases the rate of calcium release, suggesting that the ability of the DHPR to trigger calcium release and to function as a calcium channel is impaired by this agent.
MATERIALS AND METHODS
The experiments were approved by the Animal Care and Use Committee of the University of Illinois at Chicago and were conducted according to the Guide for the Care and Use of Laboratory Animals (National Academy of Sciences, Washington, DC, 1996) .
Skeletal myotube cultures. Primary cultures of skeletal muscle tissues were prepared as previously described (14) . Skeletal muscle of newborn mice was removed and finely minced. The small pieces of muscle were incubated at 37°C for 30-45 min in Ca 2ϩ , Mg 2ϩ -free rodent Ringer (in mM: 155 NaCl, 5 KCl, 11 glucose, and 10 HEPES, pH 7.4) containing collagenase type IA (1 mg/ml) (Sigma Chemical, St. Louis, MO). Dissociated muscle was triturated with a Pasteur pipette in plating medium [vol/vol, 80% Dulbecco's modified Eagle's medium (DMEM) with 4.5 g/l glucose, 10% horse serum, and 10% calf serum]. Large debris was removed from the solution by filtration and centrifugation, and a suspension of myocytes was obtained. Cultures were maintained in a 37°C incubator with a gas mixture of 95% air and 5% CO 2. Skeletal myotubes were studied at 7-10 days after initial plating, and all experiments were preformed at room temperature.
Charge movement measurements. The whole cell configuration of the patch-clamp technique (20) was used for measurement of intramembrane charge movement, calcium transients, and I Ca,L in skeletal myotubes. Data acquisition was synchronized with pulse generation by a personal computercontrolled 12-bit analog-to-digital/digital-to-analog Digidata 1200A converter. Linear components of the membrane were digitally subtracted by appropriate scaling and subtracting negative control currents that do not activate ionic conductances. Membrane capacitance was measured by integrating the area under the capacity transient before series resistance compensation and was used to normalize the charge moved and I Ca,L measurements obtained from different myotubes. Data acquisition and processing were performed with pCLAMP 7.0 software (Axon Instruments). Recording electrodes were pulled from borosilicate glass and had resistances between 1.6 and 2.0 M⍀ when filled with a solution containing (in mM) 140 Cs-aspartate, 5 Mg 2Cl, 10 Cs-EGTA, and 10 HEPES, pH 7.4 adjusted with CsOH. The extracellular solution used to record charge movement contained (in mM) 145 TEACl, 2 CaCl 2, 10 HEPES, 8 MgCl2, 0.5 CdCl2, 0.1 LaCl3, and 0.003 TTX, pH 7.4 adjusted with CsOH. For calcium transients and ICa,L recording, the extracellular solution contained 145 TEACl, 10 CaCl2, 10 HEPES, and 0.003 TTX, pH 7.4 adjusted with CsOH. Gating currents were elicited with 15-ms test pulses delivered from a holding potential of Ϫ80 mV in 10-mV increments from Ϫ40 to ϩ60 mV. To isolate gating currents due to DHPRs and minimize contributions of gating currents from T-type, potassium, and sodium channels, we used a prepulse protocol, as described in Adams et al. (1) . In this protocol, a 1-s depolarizing pulse to Ϫ30 mV is followed by a 25-ms repolarization to Ϫ50 mV and test pulses of varying amplitude. This voltage-dependent mechanism was used to partially immobilize the movement of positively charged amino acids or voltage sensors. The portion of charge movement resistant to the effect of a prepulse, herein referred to as Q r, represents the gating current of the DHPR, whereas the component of total charge (Qt) that is sensitive to the prepulse (Qs) presumably represents gating currents from T-type, potassium, and sodium channels (1).
To determine the nifedipine-sensitive component of the gating current, paired recordings were performed in the absence and presence of 10 M nifedipine (Sigma Chemical). GBP was kindly provided by Parke-Davis Research Laboratories (Warner-Lambert, Ann Arbor, MI). Skeletal muscle cells were incubated with 50 M GBP for 1 h before examination, and it was maintained in the external recording solution. Figure 1 shows the dose-response curve of the inhibition of I Ca,L amplitude by GBP. From the normalized inhibition, we calculated an IC50 of 13.9 M. This value of IC50 is comparable to those previously reported. Stefani et al. (32) determined an IC 50 of 3.65 M for isolated cortex neurons, 13.84 M for striatum neurons, and 4.52 M for globus pallidus neurons. Wamil and McLean (37) determined that the value of IC 50 decreased with time of exposure to GBP. The IC50 was 130 M for recordings obtained before 60 s after the application of GBP, 19 M for recordings obtained between 10 and 60 min (this time and concentration are equivalent to our studies), and 4 M for 12-48 h.
Calcium transient measurements. Changes in intracellular calcium concentration were measured with the cell-impermeant fluorescent dye K 5Fluo-3 (200 M; Molecular Probes), as previously described (14) . Individual cells were directly loaded through the patch pipette with Fluo-3 added to the internal solution (contents listed above). Fluorescence emission was collected with a photomultiplier tube mounted to the side port of a Nikon Diaphot 300 inverted microscope. The set of filters used for calcium measurements was as follows: excitation centered at 470 nm (Ϯ20 nm); dichroic long-pass mirror centered at 510 nm; and long-pass emission filter centered at 520 nm. The background fluorescence was measured for each myotube in the cell-attached mode before opening of the patch pipette. Measurement of changes in intracellular calcium concentration was expressed as ⌬F/F (14), where ⌬F denotes an increase in fluorescence from baseline values and F is baseline fluorescence measured before depolarization. Transients were recorded simultaneously with I Ca,L and were elicited with 100-ms test pulses using the prepulse protocol. Curve fitting and statistical analysis. For each cell, the voltage dependence of charge movement, calcium transient (⌬F/F), and calcium conductance (G) was fitted to a Boltzmann distribution
where Ymax was either Qmax, (⌬F/F)max, or Gmax; V1⁄2 is the membrane potential where Y ϭ Ymax /2, and k is the slope factor. Data were analyzed using analysis of variance with repeated measures and are expressed as means Ϯ SE. Statistical analysis was performed using Statistica 5.1 (StatSoft, Tulsa, OK). Significance for all data was set at P Յ 0.05.
RESULTS

Effect of depolarizing prepulse on charge movement, calcium transients, and I Ca,L .
We used a prepulse protocol to isolate the events resulting from activation of DHPRs. Figure 2A shows records of charge movement obtained from skeletal myotubes in the absence and representative records of gating currents obtained in the absence (Ϫ) or presence (ϩ) of a depolarizing prepulse to Ϫ30 mV. Membrane potential for both sets of records is indicated at left. The graph (right) shows that the average gating current densities elicited in the absence of a prepulse (F; n ϭ 31) were significantly reduced compared with gating currents elicited with a 1-s prepulse to Ϫ30 mV (OE; n ϭ 27) (*P Ͻ 0.05). Q, charge movement. B: calcium transients (left) elicited in the absence of a prepulse were not significantly different from those elicited with a 1-s depolarizing prepulse to Ϫ30 mV (n ϭ 7). The graph (right) shows the voltage dependence of calcium transients (⌬F/F) in the absence (F) and presence (OE) of a prepulse. C: ICa,L were elicited using voltage steps with (OE) and without (F) (n ϭ 14) a 1-s depolarizing prepulse to Ϫ30 mV. Maximum ICa,L densities were not significantly different between the groups, as shown by the graph (right). presence of a prepulse at different test potentials. The voltage dependence of the total charge movement and the charge resistant to a depolarizing prepulse are shown in the graph in Fig. 2A . The difference between the total and resistant charges represents the charge that can be inactivated by the prepulse and corresponds to voltage-sensitive channels other than the DHPR (1). The average amount of Q t was 9.5 Ϯ 0.9 nC/F, and the average of Q r was 5.2 Ϯ 0.6 nC/F (n ϭ 27). These values of charge movement are in close agreement with values previously reported (1, 16, 28) . The curve corresponding to Q t has a more negative V1⁄2 (Ϫ16.8 Ϯ 1.1 mV) than the Q r curve (Ϫ6.2 Ϯ 1.7 mV) because it contains charge from voltage-dependent proteins that activate at lower membrane potentials than the DHPR. The average value of k was 10.21 Ϯ 0.6 and 12.36 Ϯ 0.5 mV in the absence and presence of the prepulse, respectively.
In contrast to the decrease of charge movement with a depolarizing prepulse, neither calcium transients (⌬F/F) nor I Ca,L showed changes in amplitude or voltage dependence. The graph in Fig. 2B shows calcium transients in the absence and presence of a prepulse and the fluorescence-voltage relationship. The average maximum ⌬F/F was 1.37 Ϯ 0.12 and 1.34 Ϯ 0.13 (n ϭ 7) in the absence and presence of a prepulse, respectively. Figure 2C shows the data corresponding to I Ca,L . The current-voltage relationships overlap over the entire voltage range tested. The maximum I Ca,L recorded was, on average, Ϫ9.6 Ϯ 0.9 and Ϫ10.0 Ϯ 1.0 pA/pF (n ϭ 14) in the absence or presence of the prepulse, respectively. Thus, as previously suggested (16) , these data indicate that the immobilization-resistant charge movement (Q r ) is closely related to calcium release and I Ca,L in skeletal muscle. We therefore used this experimental paradigm to study potential effects of GBP on Q r , calcium transients, and I Ca,L .
Increase of immobilization-resistant charge movement by GBP. When skeletal myotubes were exposed to GBP, we found a large increase in Q r compared with untreated myotubes. Figure 3A shows representative records of Q r obtained in the absence and presence of GBP. The values of Q r were averaged at each membrane potential and used to construct the voltage dependence shown in Fig. 3B . The increase in Q r in the presence of GBP was observed for membrane potentials from Ϫ30 to 60 mV. The average maximum Q r in GBP-treated and control myotubes was 8.9 Ϯ 0.9 (n ϭ 23) and 5.1 Ϯ 0.6 nC/F (n ϭ 31), respectively (P Ͻ 0.05). The average values of the other parameters describing the voltage dependence in GBP-treated myotubes were V1 ⁄2 ϭ Ϫ8.0 Ϯ 3.8 mV and k ϭ 13.2 Ϯ 1.3 mV (n ϭ 23), whereas the corresponding values for control myotubes were V1⁄2 ϭ Ϫ6.2 Ϯ 1.9 mV and k ϭ 12.36 Ϯ 0.5 mV (n ϭ 31). The difference in the parameters of voltage dependence between the two conditions was not significant (P Ͼ 0.05). The graph in Fig. 3B shows normalized Q r to the maximum value for GBPtreated and control myotubes, where the similarity of the voltage dependence can be better appreciated. Because Q r is thought to represent the movement of the DHPR voltage sensor in the membrane, the increase in Q r indicates that GBP facilitates the movement of the receptor, yet it does not modify the voltage dependence.
Effect of GBP on calcium transients. Figure 4 shows typical calcium transients elicited from a control myotube (Fig. 4A) and a GBP-treated myotube (Fig. 4B) at Ϫ30, 0, and 50 mV. Calcium transients were also elicited with the prepulse protocol. The maximum amplitude of the calcium transients, measured at the end of the pulse, in GBP-treated myotubes (⌬F/F ϭ 1.15 Ϯ 0.19; n ϭ 14) was similar to the amplitude of the transients recorded from control myotubes (1.25 Ϯ 0.14; n ϭ 20) (P Ͼ 0.05). The average values of V1 ⁄2 and k for GBP-treated myotubes were Ϫ0.56 Ϯ 1.7 and 6.23 Ϯ 0.4 mV (n ϭ 14), respectively, and for control Figure 4 , C and D, shows the voltage dependence of calcium transients in absolute and normalized values, respectively, to demonstrate that the parameters of activation were not modified (P Ͼ 0.05).
We further analyzed calcium transients by calculating the derivative of the records. Under our recording conditions, the derivative provides an accurate approximation of the rate of release in skeletal myotubes (27) . It has been shown that myotubes have a negligible calcium removal flux (14) , which can be neglected if a large concentration of calcium buffers is present in the sarcoplasm. In our experiments, the intracellular solution contained 10 mM EGTA and 0.2 mM Fluo-3, which represent a high concentration of calcium buffers in these cells. Moreover, the rate of calcium release from the SR is much faster than the rate of removal (25) . Derivative traces are shown below the corresponding calcium transient records in Fig. 4, A and B . As seen from these traces, GBP caused a reduction in the rate of rise of calcium transients, reflecting a smaller rate of release, compared with control myotubes. The graph in Fig. 4E shows that the reduction in the rate of rise of the transient was significant at membrane potentials from 10 to 60 mV. These data demonstrate that, despite the increase in Q r , GBP did not affect the maximum amplitude or the voltage dependence of the transients but caused a significant decrease in the rate of calcium release.
Effect of GBP on I Ca,L and conductance. GBP caused a small but significant reduction of I Ca,L at membrane potentials between 20 and 40 mV compared with control cells, as shown in Fig. 5 . Figure 5A shows typical records of I Ca,L in untreated and GBP-treated myotubes at different membrane potentials. The conductance of the calcium channel was calculated by fitting the I Ca,L data to a Boltzmann equation:
, where I(V) is the maximum I Ca,L at a given test potential, G max L is the maximum L-type channel conductance, V r is the reversal potential for calcium, V is the test potential, V L is the half-maximal activation potential for the L-type To examine the time course of activation of I Ca,L , the rising phase of the traces was fitted to a second-order exponential function. Because the activation of I Ca,L mediated by DHPRs in skeletal myotubes is voltage independent (8), the analysis was performed at the membrane potential where the current was maximal for each cell. Figure 5D shows an example of the curve fitting superimposed on original I Ca,L records for a control and a GBP-treated myotube. In both cases, the curves entirely overlapped the I Ca,L traces. We found that neither the slow ( slow ) nor the fast time constants ( fast ) of activation were significantly different between the control and GBP-treated myotubes (Fig. 5E) . The average values of slow were 57.6 Ϯ 1.76 and 54.93 Ϯ 1.67 ms, and for fast the values were 6.65 Ϯ 0.42 and 7.66 Ϯ 0.86 ms, for control (n ϭ 41) and GBP-treated (n ϭ 24) myotubes, respectively.
Nifedipine blocks enhancement of Q r by GBP. Because GBP increased Q r while decreasing both the rate of calcium release and I Ca,L , it could be argued that a voltage-sensitive membrane protein other than the DHPR produced the additional charge movement recorded in GBP-treated cells. We tested this hypothesis by using nifedipine, a specific DHPR blocker. Recordings of Q r in the absence and the presence of 10 M nifedipine were obtained from control and GBP-treated myotubes, as shown in Fig. 6A . On average, nifedipine decreased the maximum Q r to a larger extent in GBPtreated myotubes (60 Ϯ 3%, n ϭ 16) compared with the reduction in untreated myotubes (25 Ϯ 3.5%; n ϭ 25). Thus the application of nifedipine equalized the amount of maximum Q r in control (3.9 Ϯ 0.3 nC/F; n ϭ 25) and GBP-treated myotubes (3.6 Ϯ 0.3 nC/F; n ϭ 16), as shown in Fig. 6B . The percent reduction in Q r by nifedipine in control myotubes is consistent with other studies. For example, Strube et al. (33) showed a 33% reduction in charge movement (Q t ) from developing skeletal muscle. The decrease of Q r in myotubes treated with GBP and nifedipine thus indicates that the extra charge recorded from GBP-treated myotubes is indeed generated by the DHPR. Figure 6B shows the Q r -voltage relationships obtained for untreated and GBP-treated myotubes. The amount of Q r elicited at each membrane potential in the presence of nifedipine was similar in both groups. Figure 6C shows the data normalized to the maximum Q r as a function of membrane potential. The voltage dependence of Q r was unaltered by nifedipine. The average values of V1 ⁄2 and k for myotubes treated with nifedipine alone were Ϫ12.8 Ϯ 1.4 and 11.6 Ϯ 0.4 mV (n ϭ 25), respectively. For myotubes treated with GBP and nifedipine, the average values were V1⁄2 ϭ Ϫ10.41 Ϯ 2.0 and k ϭ 11.8 Ϯ 0.7 mV (n ϭ 16).
GBP decreases the effectiveness of the DHPR in E-C coupling. To have an objective measure of the dissociation of Q r and calcium release and I Ca,L caused by GBP, we compared the rate of release and conductance as a function of Q r . These data are shown in Fig. 7 for control and GBP-treated myotubes. As shown, GBP shifted the curves to the right, which indicates that more immobilization-resistant charge is needed to attain similar levels of rate of release or conductance. The amount of Q r required for the same value of rate of release or conductance was roughly two times greater in the presence of GBP than the amount of Q r required in control myotubes. Moreover, in GBP-treated myotubes, the maximum rate of release did not reach control levels. Thus this analysis indicates that GBP decreased the effectiveness of the DHPR as a voltage sensor necessary for calcium release and as a calcium channel.
DISCUSSION
We report a novel regulatory effect of GBP on the E-C coupling mechanism in skeletal muscle. The effect is characterized by dissociation of Q r from calcium release and I Ca,L . Two lines of evidence indicate that GBP exerted its effects by acting on the DHPR. First, GBP did not modify the midpoint potential of activation (V1 ⁄2) or the slope (k) of the curves of any of the events produced by activation of the DHPR. Second, the increase of Q r caused by GBP was antagonized by nifedipine, such that the amount of Q r remaining in the presence of GBP and nifedipine was similar to that in myotubes treated with nifedipine alone.
Based on the voltage dependence and time course of activation of Q r , calcium release, and I Ca,L , a sequential scheme of the conformational changes in the DHPR has been proposed (16) . This model would predict that any agent that modifies Q r would have a similar effect on calcium release and I Ca,L . However, other studies have shown that perchlorate and nifedipine may also have differential effects on the events generated by the DHPR (6, 22) . The target proteins involved in the actions of perchlorate are thought to be the ␣ 1 1.1-subunit of the DHPR and/or the RyR1 (24), whereas nifedipine acts on the ␣ 1 1.1-subunit (39) , where its binding site is localized (26) . In this respect, the effect of GBP on E-C coupling is unique because the ␣ 2 /␦-subunit has been identified as the GBP receptor (17) , and its binding site has been localized on the extracellular portion of the ␣ 2 /␦ 1 -subunit of the DHPR (4, 38) .
The remote possibility exists that the effect of GBP on E-C coupling is unrelated to its interaction with the ␣ 2 /␦ 1 -subunit and that GBP may also bind to the ␣ 1 1.1 subunit (in addition to the ␣ 2 /␦ 1 -subunit) because of the concentration of the drug used in these experiments (50 M). However, calculation of the slope of the curve fitted to the data in Fig. 1 resulted in a value of 1.05, indicating that GBP bound to a single population of sites in myotubes. This result agrees with previous studies by Gee et al. (17) using rat muscle membranes, where GBP also bound to one population of sites. Furthermore, radioligand binding and immunoblotting studies of fractionated L-type calcium channels isolated from skeletal muscle determined that GBP bound to the ␣ 2 /␦ 1 -subunit even at high concentrations. Thus it is conceivable that the effects of GBP on E-C coupling we have elucidated are mediated by the ␣ 2 /␦ 1 -subunit.
Our results suggest that GBP binding to the ␣ 2 /␦ 1 -subunit would affect the conformational changes experienced by the ␣ 1 1.1-subunit during DHPR activation. Only a few amino acids of the ␣ 2 /␦ 1 protein are found on the cytoplasmic side of the membrane, the remainder being located either within the membrane or on the extracellular side (18) . For this reason, it is attractive to hypothesize that the GBP-␣ 2 /␦ 1 -subunit complex acts on the transmembrane repeats and perhaps the outer portion of the ␣ 1 1.1-subunit. Initially the interaction between the GBP-␣ 2 /␦ 1 -subunit complex and ␣ 1 1.1 would favor the movement of the repeats resulting in a larger Q r . Subsequently, the complex would prevent the fast and complete change of repeats II and III (and the II-III cytoplasmic loop). This would result in slower activation of the RyR1 and an attenuated rate of calcium release. Finally, the decrease in I Ca,L amplitude may be explained by a blocking effect of the GBP-␣ 2 /␦ 1 -subunit complex. The block may occur on the extracellular side of the calcium channel because it has been shown that the external portion of the ␣ 2 /␦ 1 -subunit is required for current stimulation (18) . Although repeat I in the ␣ 1 1.1-subunit is thought to set the activation rate of the I Ca,L (35), we do not believe the complex is modifying the movement of repeat I because the time constants of activation of the current were similar in untreated and GBP-treated myotubes.
Whether the GBP-binding properties to the ␣ 2 /␦ 1 -subunit in skeletal myotubes are independent of the presence or absence of a prepulse cannot be determined from our experiments. As Adams et al. (1) have previously shown and we mentioned earlier, we need to use a prepulse to record the activity of the DHPR separate from other voltage-dependent proteins in skeletal myotubes. However, we have previously shown that the effect of GBP on neuronal calcium channels is noticed only after the application of a prepulse (2) .
In recent studies using expression systems, other investigators have shown that charge movement arising from the cardiac ␣ 1 1.2-subunit is modulated by coexpression of the ␣ 2 /␦-subunit (3, 29, 31) . Although the experimental systems between those reports and this manuscript are different and calcium transients were not studied earlier, they agree with our finding that the ␣ 2 /␦ 1 -subunit may control the gating of the ␣ 1 1.1-peptide. However, we further consider that the in situ function of the ␣ 2 /␦ 1 -subunit may be to effectively couple gating current with calcium release and channel opening.
Taken together the data presented in this work suggest the presence of several closed states before the DHPR is fully activated and that these states can be affected by GBP. Our results are also the first to provide information about the involvement of the ␣ 2 / ␦ 1 -subunit in skeletal muscle E-C coupling.
